ArticleProceedings of the National Academy of Sciences of the United States of America2019
Pre-detection history of extensively drug-resistant tuberculosis in KwaZulu-Natal, South Africa.
Registry-linked trialAbstract read
In one paragraph
Article in Proceedings of the National Academy of Sciences of the United States of America, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05633056 (Adaptive Evaluation of mHealth and Conventional Adherence Support Interventions to Optimize Outcome With New Treatment Regimens for Drug-resistant Tuberculosis and HIV in South Africa), which is not on this map. Cited by 18 papers.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Adaptive Evaluation of mHealth and Conventional Adherence Support Interventions to Optimize Outcome With New Treatment Regimens for Drug-resistant Tuberculosis and HIV in South Africa
Who cites it
18 citing papers in PubMed.
- Mixed-strain infection and heteroresistance in drug-resistant tuberculosis: insights from a whole-genome sequencing pilot.Frontiers in epidemiology · 2026Article
- Transmission of bedaquiline-resistant Mycobacterium tuberculosis in KwaZulu-Natal, South Africa.American journal of respiratory and critical care medicine · 2026Article
- Beyond Hotspot Mutations: Diagnostic Relevance of High Frequency, Low Frequency, and DisputedPathogens (Basel, Switzerland) · 2025Review
- Molecular Epidemiology of Mycobacterium tuberculosis Across 3 Distinct Geographic Sites in South Africa.The Journal of infectious diseases · 2025Article
- Ecology, global diversity and evolutionary mechanisms in the Mycobacterium tuberculosis complex.Nature reviews. Microbiology · 2025Review
- Isoniazid and Rifampicin Resistance-Conferring Mutations inPathogens (Basel, Switzerland) · 2023Review
- Bedquiline Resistance Mutations: Correlations with Drug Exposures and Impact on the Proteome in M. tuberculosis.Antimicrobial agents and chemotherapy · 2023Article
- Connecting the dots: understanding how human mobility shapes TB epidemics.Trends in microbiology · 2022Review
- Transcontinental spread and evolution of Mycobacterium tuberculosis W148 European/Russian clade toward extensively drug resistant tuberculosis.Nature communications · 2022Article
- Mutations compensating for the fitness cost of rifampicin resistance in Escherichia coli exert pleiotropic effect on RNA polymerase catalysis.Nucleic acids research · 2022Article
- Article
- Evolution and emergence of multidrug-resistantMicrobial genomics · 2021Article
- Chemical Classes Presenting Novel Antituberculosis Agents Currently in Different Phases of Drug Development: A 2010-2020 Review.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Genomic epidemiology of tuberculosis in eastern Malaysia: insights for strengthening public health responses.Microbial genomics · 2021Article
- Multiple Merger Genealogies in Outbreaks of Mycobacterium tuberculosis.Molecular biology and evolution · 2021Article
- Evolution of Drug-ResistantFrontiers in microbiology · 2021Review
- MycoVarP: Mycobacterium Variant and Drug Resistance Prediction Pipeline for Whole-Genome Sequence Data Analysis.Frontiers in bioinformatics · 2021Article
- Whole Genome Analysis Detects the Emergence of a SingleFrontiers in microbiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Tyler S BrownDepartment of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY 10032.ORCID 0000-0003-2559-2789
Lavanya ChallagundlaDepartment of Microbiology and Immunology, University of Mississippi Medical Center, Jackson, MS 39216.
Evan H BaughInstitute for Genomic Medicine, Columbia University, New York, NY 10032.
Shaheed Vally OmarCentre for Tuberculosis, National Institute for Communicable Diseases, Johannesburg 2131, South Africa.
Arkady MustaevPublic Health Research Institute of New Jersey Medical School, Rutgers University, Newark, NJ 07103.
Sara C AuldDivision of Pulmonary, Allergy, Critical Care and Sleep Medicine, Emory University School of Medicine, Atlanta, GA 30322.
N Sarita ShahDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA 30322.
Barry N KreiswirthPublic Health Research Institute of New Jersey Medical School, Rutgers University, Newark, NJ 07103.
James C M BrustDivisions of General Internal Medicine and Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine, Bronx, NY 10467.
Kristin N NelsonDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA 30322.
Apurva NarechaniaInstitute for Comparative Genomics, American Museum of Natural History, New York, NY 10024.
Natalia KurepinaPublic Health Research Institute of New Jersey Medical School, Rutgers University, Newark, NJ 07103.
Koleka MlisanaDepartment of Medical Microbiology, School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban 4001, South Africa.
Richard BonneauCenter for Computational Biology, Flatiron Institute, New York, NY.
Vegard EldholmDivision of Infection Control and Environmental Health, Norwegian Institute of Public Health, 0456 Oslo, Norway.ORCID 0000-0001-6721-3375
Nazir IsmailCentre for Tuberculosis, National Institute for Communicable Diseases, Johannesburg 2131, South Africa.
Sergios-Orestis KolokotronisInstitute for Comparative Genomics, American Museum of Natural History, New York, NY 10024.ORCID 0000-0003-3309-8465
D Ashley RobinsonDepartment of Microbiology and Immunology, University of Mississippi Medical Center, Jackson, MS 39216.
Neel R GandhiDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA 30322.
Barun MathemaDepartment of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY 10032; bm2055@cumc.columbia.edu.
Funding
Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Carlos del Rio · 2002 to 2026
$74.0MPatient and Population Health Outcomes Research SWGP30AI124414 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI HARRIS GOLDSTEIN · 2017 to 2026
$28.3MCTSA Administrative Supplement for Informatics Core: A novel AI/ML system to predict respiratory failure and ARDS in Covid-19 patientsUL1TR002556 · NCATS · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI KELLER, MARLA J, KIM, MIMI Y · 2018 to 2022
$26.7MCore-010UL1TR001073 · NCATS · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI KELLER, MARLA J, SHAMOON, HARRY · 2013 to 2017
$21.3MRole of antigen-specific T cell responses in the control of TBU19AI111211 · NIAID · EMORY UNIVERSITY · PI ALTMAN, JOHN DAVID · 2014 to 2020
$20.1MINFECTIOUS DISEASE AND BASIC MICROBIOLOGICAL MECHANISMST32AI007061 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Marcia B Goldberg · 1985 to 2026
$12.1MImpact of HIV, Antiretroviral Therapy and TB Genotype on Survival in MDR TBR01AI087465 · NIAID · EMORY UNIVERSITY · PI GANDHI, NEEL RAJNIKANT · 2010 to 2014
$3.9MThe Role of Casual Contact and Migration in XDR TB Transmission in South Africa: a Geospatial, Genomic and Social Network StudyR01AI138646 · NIAID · EMORY UNIVERSITY · PI MLISANA, KOLEKA P, SHAH, NIPPIE SARITA · 2018 to 2022
$3.8MTransmission of HIV-Associated XDR TB in Rural South AfricaR01AI089349 · NIAID · EMORY UNIVERSITY · PI GANDHI, NEEL RAJNIKANT · 2010 to 2014
$3.7MSafety, pharmacokinetics, and resistance to bedaquiline in XDR TB and HIVR01AI114304 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI BRUST, JAMES C M · 2015 to 2019
$3.7MMentorship in Patient-Oriented Research in Tuberculosis, HIV and Global HealthK24AI114444 · NIAID · EMORY UNIVERSITY · PI GANDHI, NEEL RAJNIKANT · 2014 to 2023
$1.8MImpact of HIV infection on early responses to TB exposureK23AI134182 · NIAID · EMORY UNIVERSITY · PI AULD, SARA · 2018 to 2023
$972kNCATS NIH HHS UL1 TR001073NCATS NIH HHS UL1 TR002556NIAID NIH HHS K23 AI134182NIAID NIH HHS K24 AI114444NIAID NIH HHS P30 AI050409NIAID NIH HHS P30 AI124414NIAID NIH HHS R01 AI087465NIAID NIH HHS R01 AI089349NIAID NIH HHS R01 AI114304NIAID NIH HHS R01 AI138646NIAID NIH HHS T32 AI007061NIAID NIH HHS U19 AI111211
Abstract
Antimicrobial-resistant (AMR) infections pose a major threat to global public health. Similar to other AMR pathogens, both historical and ongoing drug-resistant tuberculosis (TB) epidemics are characterized by transmission of a limited number of predominant
Indexed as
Evolution, MolecularExtensively Drug-Resistant TuberculosisGenome, BacterialHIV InfectionsHumansMycobacterium tuberculosisPhylogenyPhylogeographyProspective StudiesSouth AfricaWhole Genome Sequencingantimicrobial resistanceepidemicsinfectious diseasepopulation geneticstuberculosis
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
NCT05633056ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.